Zobrazeno 1 - 10
of 64
pro vyhledávání: '"U. Coppetelli"'
Autor:
V. Filipponi, M. Antonacci, M. C. Scerpa, U. Coppetelli, S. Perrone, N. Cenfra, S. Mecarocci, L. Fiori, F. Brinchi Giusti, P. Giovangrossi, F. Equitani, E. Ortu La Barbera, G. Cimino
Publikováno v:
HemaSphere, Vol 6, Pp 1223-1224 (2022)
Externí odkaz:
https://doaj.org/article/a26db4e84b334408b8435a4201ea53b9
Autor:
A. Rago, O. Annibali, V. Tomarchio, A. Fiorini, F. Fazio, U. Coppetelli, L. De Rosa, E. Papa, M.P. Bianchi, G. Antolino, T. Caravita di Toritto
Publikováno v:
Hematology Reports, Vol 12, Iss s1 (2020)
Introduction: Multiple Myeloma (MM) mostly affects elderly patients (median age of 69 years). The standard regimens and the development of novel therapies followed by autologous stem cell transplantation (ASCT) improved clinical outcomes.. In fact, t
Externí odkaz:
https://doaj.org/article/90121aac4f0b434982761f7b8fa3946e
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:S144-S145
Autor:
Tommaso Za, Agostina Siniscalchi, M.T. Petrucci, Maria Cantonetti, L. De Rosa, Alessandro Andriani, Giusy Antolino, T. Caravita di Toritto, Ombretta Annibali, Alfonso Piciocchi, G. La Verde, U Coppetelli, Federico Vozella, Manuela Rizzo, V. De Stefano, Giuseppe Cimino
Publikováno v:
Annals of hematology. 100(4)
Daratumumab (DARA) is a human IgG-K monoclonal antibody (MoAb) targeting CD38 that is approved alone or in combination with bortezomib and dexamethasone or lenalidomide and dexamethasone for relapsed or refractory MM (RRMM) in patients previously exp
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Federico Vozella, Giusy Antolino, Giacinto La Verde, Luca De Rosa, Agostina Siniscalchi, Tommaso Za, Alessandro Andriani, Maria Cantonetti, Manuela Rizzo, Maria Teresa Petrucci, Valerio De Stefano, U Coppetelli, Giuseppe Cimino, Robin Foà, Ombretta Annibali, Tommaso Caravita di Toritto, Alfonso Piciocchi
Publikováno v:
Blood. 132:5634-5634
Introduction .Treatment of multiple myeloma (MM) patients (pts) has radically changed over the last years following the introduction of next generation proteasome inhibitors (PI) and immunomodulatory derivatives (IMiDs). Despite the improvement of pt
Autor:
U. Coppetelli, U. Paladini, Simonetta Pupella, Luca Pierelli, Gaspare Adorno, Michele Vacca, Nicola Piccirillo, M. L. Foddai, Maddalena Maresca, Maria Gozzer
Publikováno v:
Vox Sanguinis. 91:126-134
Background and Objectives Stem cell collection is a standard procedure for the procurement of autologous grafts to rescue myelosuppression induced by high-dose treatments. Accurate prediction of collection yields may contribute to optimize planning a
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Tommaso Caravita di Toritto, Laura Corvatta, Daniele Derudas, Pietro Leoni, Claudia Cellini, Marino Brunori, Patrizia Caraffa, Massimo Offidani, Patrizia Mondello, Silvia Gentili, Sara Galimberti, Alessandro Andriani, Alessandro Gozzetti, Laura Maracci, Attilio Olivieri, Stelvio Ballanti, Anna Mele, Paolo Fraticelli, Patrizia Tosi, Stefano Pulini, U Coppetelli, Antonio Ledda, Francesco Alesiani, Lara Malerba, Anna Marina Liberati, Immacolata Attolico
Bendamustine, a bi-functional alkylating agent comprising a purine-like benzimidazole ring an a nitrogen mustard group, exerts a peculiar mechanism of action if compared to most conventional alkylators and this may partially explain its effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a05aa09f9641f79636517a340f5dfadf
http://hdl.handle.net/11568/680288
http://hdl.handle.net/11568/680288
Autor:
M.T. Petrucci, Giuseppe Avvisati, Marco Montanaro, Velia Bongarzoni, M De Muro, A Zullo, Tommaso Caravita, Nicoletta Villivà, U Coppetelli, Agostina Siniscalchi, Domenico Gaglioti, Anna Levi, Francesco Pisani, A Andriani, Alessandro Agrillo
Publikováno v:
Blood Cancer Journal
Bisphosphonates (BPs) are used intravenously to treat cancer-related conditions for the prevention of pathological fractures. Osteonecrosis of the jaw (BRONJ) is a rare complication reported in 4-15% of patients. We studied, retrospectively, 55 patie